MedPath

Arvinas Androgen Receptor, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer

Phase 1
Completed
Conditions
Metastatic Prostate Cancer
Interventions
Drug: ARV-110 in Combination with Abiraterone
First Posted Date
2022-01-04
Last Posted Date
2025-07-25
Lead Sponsor
Arvinas Androgen Receptor Inc.
Target Recruit Count
4
Registration Number
2024-516661-37-00
Locations
🇫🇷

Assistance Publique Hopitaux De Paris, Paris, France

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer Metastatic
Interventions
First Posted Date
2019-03-25
Last Posted Date
2025-04-01
Lead Sponsor
Arvinas Androgen Receptor, Inc.
Target Recruit Count
248
Registration Number
NCT03888612
Locations
🇺🇸

Clinical Trial Site, Charlottesville, Virginia, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.